SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human
Antibodies directed against CD22 have been used in radioimmunotherapy (RIT) clinical trials to treat patients with diffuse large B-cell lymphoma (DLBCL) with promising results. However, relevant preclinical models are needed to facilitate the evaluation and optimization of new protocols. Spontaneous...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00020/full |
| _version_ | 1819169188669816832 |
|---|---|
| author | Floriane Etienne Floriane Etienne Maxime Berthaud Frédérique Nguyen Frédérique Nguyen Karine Bernardeau Karine Bernardeau Catherine Maurel Caroline Bodet-Milin Caroline Bodet-Milin Maya Diab Jérôme Abadie Jérôme Abadie Valérie Gouilleux-Gruart Aurélien Vidal Mickaël Bourgeois Mickaël Bourgeois Nicolas Chouin Nicolas Chouin Catherine Ibisch Catherine Ibisch François Davodeau |
| author_facet | Floriane Etienne Floriane Etienne Maxime Berthaud Frédérique Nguyen Frédérique Nguyen Karine Bernardeau Karine Bernardeau Catherine Maurel Caroline Bodet-Milin Caroline Bodet-Milin Maya Diab Jérôme Abadie Jérôme Abadie Valérie Gouilleux-Gruart Aurélien Vidal Mickaël Bourgeois Mickaël Bourgeois Nicolas Chouin Nicolas Chouin Catherine Ibisch Catherine Ibisch François Davodeau |
| author_sort | Floriane Etienne |
| collection | DOAJ |
| description | Antibodies directed against CD22 have been used in radioimmunotherapy (RIT) clinical trials to treat patients with diffuse large B-cell lymphoma (DLBCL) with promising results. However, relevant preclinical models are needed to facilitate the evaluation and optimization of new protocols. Spontaneous DLBCL in dogs is a tumor model that may help accelerate the development of new methodologies and therapeutic strategies for RIT targeting CD22. Seven murine monoclonal antibodies specific for canine CD22 were produced by the hybridoma method and characterized. The antibodies' affinity and epitopic maps, their internalization capability and usefulness for diagnosis in immunohistochemistry were determined. Biodistribution and PET imaging on a mouse xenogeneic model of dog DLBCL was used to choose the most promising antibody for our purposes. PET-CT results confirmed biodistribution study observations and allowed tumor localization. The selected antibody, 10C6, was successfully used on a dog with spontaneous DLBCL for SPECT-CT imaging in the context of disease staging, validating its efficacy for diagnosis and the feasibility of future RIT assays. This first attempt at phenotypic imaging on dogs paves the way to implementing quantitative imaging methodologies that would be transposable to humans in a theranostic approach. Taking into account the feedback of existing human radioimmunotherapy clinical trials targeting CD22, animal trials are planned to investigate protocol improvements that are difficult to consider in humans due to ethical concerns. |
| first_indexed | 2024-12-22T19:15:32Z |
| format | Article |
| id | doaj.art-7e71b67d23e4426780eb2e53d47f0a08 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T19:15:32Z |
| publishDate | 2020-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-7e71b67d23e4426780eb2e53d47f0a082022-12-21T18:15:31ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-02-011010.3389/fonc.2020.00020484404SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for HumanFloriane Etienne0Floriane Etienne1Maxime Berthaud2Frédérique Nguyen3Frédérique Nguyen4Karine Bernardeau5Karine Bernardeau6Catherine Maurel7Caroline Bodet-Milin8Caroline Bodet-Milin9Maya Diab10Jérôme Abadie11Jérôme Abadie12Valérie Gouilleux-Gruart13Aurélien Vidal14Mickaël Bourgeois15Mickaël Bourgeois16Nicolas Chouin17Nicolas Chouin18Catherine Ibisch19Catherine Ibisch20François Davodeau21CRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, FranceAMaROC, Oniris (Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering), Nantes, FranceCRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, FranceCRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, FranceAMaROC, Oniris (Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering), Nantes, FranceCRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, FranceP2R “Production de Protéines Recombinantes”, CRCINA, SFR-Santé, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, FranceCRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, FranceCRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, FranceNuclear Medicine, University Hospital, Nantes, FranceCRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, FranceCRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, FranceAMaROC, Oniris (Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering), Nantes, FranceEA7501, GICC, Université de Tours, CHRU de Tours, Tours, FranceGroupement d'Intérêt Public ARRONAX Cyclotron, Saint-Herblain, FranceCRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, FranceGroupement d'Intérêt Public ARRONAX Cyclotron, Saint-Herblain, FranceCRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, FranceAMaROC, Oniris (Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering), Nantes, FranceCRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, FranceAMaROC, Oniris (Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering), Nantes, FranceCRCINA, INSERM, CNRS, Université de Nantes, Université d'Angers, Nantes, FranceAntibodies directed against CD22 have been used in radioimmunotherapy (RIT) clinical trials to treat patients with diffuse large B-cell lymphoma (DLBCL) with promising results. However, relevant preclinical models are needed to facilitate the evaluation and optimization of new protocols. Spontaneous DLBCL in dogs is a tumor model that may help accelerate the development of new methodologies and therapeutic strategies for RIT targeting CD22. Seven murine monoclonal antibodies specific for canine CD22 were produced by the hybridoma method and characterized. The antibodies' affinity and epitopic maps, their internalization capability and usefulness for diagnosis in immunohistochemistry were determined. Biodistribution and PET imaging on a mouse xenogeneic model of dog DLBCL was used to choose the most promising antibody for our purposes. PET-CT results confirmed biodistribution study observations and allowed tumor localization. The selected antibody, 10C6, was successfully used on a dog with spontaneous DLBCL for SPECT-CT imaging in the context of disease staging, validating its efficacy for diagnosis and the feasibility of future RIT assays. This first attempt at phenotypic imaging on dogs paves the way to implementing quantitative imaging methodologies that would be transposable to humans in a theranostic approach. Taking into account the feedback of existing human radioimmunotherapy clinical trials targeting CD22, animal trials are planned to investigate protocol improvements that are difficult to consider in humans due to ethical concerns.https://www.frontiersin.org/article/10.3389/fonc.2020.00020/fullcomparative oncologydogdiffuse large B-cell lymphomamonoclonal antibodySPECT-CT imagingCD22 |
| spellingShingle | Floriane Etienne Floriane Etienne Maxime Berthaud Frédérique Nguyen Frédérique Nguyen Karine Bernardeau Karine Bernardeau Catherine Maurel Caroline Bodet-Milin Caroline Bodet-Milin Maya Diab Jérôme Abadie Jérôme Abadie Valérie Gouilleux-Gruart Aurélien Vidal Mickaël Bourgeois Mickaël Bourgeois Nicolas Chouin Nicolas Chouin Catherine Ibisch Catherine Ibisch François Davodeau SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human Frontiers in Oncology comparative oncology dog diffuse large B-cell lymphoma monoclonal antibody SPECT-CT imaging CD22 |
| title | SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human |
| title_full | SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human |
| title_fullStr | SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human |
| title_full_unstemmed | SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human |
| title_short | SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human |
| title_sort | spect ct imaging of dog spontaneous diffuse large b cell lymphoma targeting cd22 for the implementation of a relevant preclinical model for human |
| topic | comparative oncology dog diffuse large B-cell lymphoma monoclonal antibody SPECT-CT imaging CD22 |
| url | https://www.frontiersin.org/article/10.3389/fonc.2020.00020/full |
| work_keys_str_mv | AT florianeetienne spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT florianeetienne spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT maximeberthaud spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT frederiquenguyen spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT frederiquenguyen spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT karinebernardeau spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT karinebernardeau spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT catherinemaurel spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT carolinebodetmilin spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT carolinebodetmilin spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT mayadiab spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT jeromeabadie spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT jeromeabadie spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT valeriegouilleuxgruart spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT aurelienvidal spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT mickaelbourgeois spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT mickaelbourgeois spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT nicolaschouin spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT nicolaschouin spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT catherineibisch spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT catherineibisch spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman AT francoisdavodeau spectctimagingofdogspontaneousdiffuselargebcelllymphomatargetingcd22fortheimplementationofarelevantpreclinicalmodelforhuman |